{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"157","value":"410"},{"groupId":"OG001","spread":"127","value":"414"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"378"},{"groupId":"OG001","value":"364"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"160","value":"498"},{"groupId":"OG001","spread":"198","value":"540"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"},{"groupId":"OG001","value":"302"}],"units":"Participants"}],"title":"Cycle 3 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"378"},{"groupId":"OG001","value":"364"}],"units":"Participants"}],"description":"The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.","id":"OG001","title":"Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 1 and 3 (Cycle length=21 days)","title":"Maximum Observed Serum Concentration (Cmax) of Atezolizumab in Arm A and Arm B","type":"SECONDARY","unitOfMeasure":"mcg/mL"}